<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>366</serviceExecutionTime><Drug id="65901"><DrugName>cilostazol + Ginkgo biloba extract (oral immediate release, arterial occlusive disease/stroke), SK Chemicals</DrugName><DrugNamesKey><Name id="42924279">Renexin</Name></DrugNamesKey><DrugSynonyms><Name><Value>cilostazol + Ginkgo biloba extract (oral immediate release, arterial occlusive disease/stroke), SK Chemicals</Value></Name><Name><Value>cilostazol + Ginexin-F (peripheral arterial occlusive disease), SK Chemicals</Value></Name><Name><Value>Renexin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>73963-72-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="26914">SK Chemicals Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="26914">SK Chemicals Co Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="26914" type="Company"><TargetEntity id="4295881451" type="organizationId">SK Discovery Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1598" type="ciIndication"><TargetEntity id="10062585" type="MEDDRA"/></SourceEntity><SourceEntity id="65" type="ciIndication"><TargetEntity id="D020521" type="MeSH"/><TargetEntity id="-1815339002" type="omicsDisease"/><TargetEntity id="93" type="siCondition"/></SourceEntity><SourceEntity id="302" type="Action"><TargetEntity id="469" type="Mechanism">Phosphodiesterase PDE3 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="659" type="Action"><TargetEntity id="3176" type="Mechanism">Inhibitors of Blood Coagulation Pathways</TargetEntity></SourceEntity><SourceEntity id="299" type="Action"><TargetEntity id="346" type="Mechanism">Platelet-Activating Factor Receptor (PAFR) Antagonists</TargetEntity></SourceEntity><SourceEntity id="6379" type="Action"><TargetEntity id="2874" type="Mechanism">Nitric Oxide Synthase Activators</TargetEntity></SourceEntity><SourceEntity id="170" type="Action"><TargetEntity id="913" type="Mechanism">Free Radical Scavengers</TargetEntity></SourceEntity><SourceEntity id="312" type="Action"><TargetEntity id="3554" type="Mechanism">Platelet Adhesion Inhibitors</TargetEntity><TargetEntity id="3985" type="Mechanism">Drugs Targeting on PolyQ-expanded Proteins</TargetEntity></SourceEntity><SourceEntity id="PTGT-01502" type="ciTarget"><TargetEntity id="149040958157243" type="siTarget">Platelet-activating factor receptor</TargetEntity><TargetEntity id="2774" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Peripheral arterial occlusive disease - South Korea - Apr-2012</FirstLaunched><FirstLaunched>Stroke - South Korea - Apr-2012</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1598">Peripheral arterial occlusive disease</Indication><Indication id="65">Stroke</Indication></IndicationsPrimary><ActionsPrimary><Action id="302">PDE 3 inhibitor</Action><Action id="22986">Prostacyclin synthase stimulator</Action><Action id="6379">Nitric oxide synthase stimulator</Action><Action id="299">Platelet activating factor receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="388">Vasodilator</Action><Action id="312">Platelet aggregation inhibitor</Action><Action id="659">Coagulation inhibitor</Action><Action id="170">Free radical scavenger</Action></ActionsSecondary><Technologies><Technology id="175">Drug combination</Technology><Technology id="661">Oral quick release formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="1647">Natural product</Technology><Technology id="595">Tablet formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>B1C</Code><Name>PLATELET AGGREGATION INHIBITORS</Name></Ephmra></EphmraCodes><LastModificationDate>2016-01-22T15:32:23.000Z</LastModificationDate><ChangeDateLast>2017-08-07T00:00:00.000Z</ChangeDateLast><AddedDate>2010-03-22T13:27:26.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="26914" linkType="Company"&gt;SK Chemicals&lt;/ulink&gt; has developed and launched Renexin, a fixed-dose combination tablet  of the phosphodiesterase 3 (PDE3) inhibitor, vasodilator and platelet aggregation inhibitor &lt;ulink linkID="13482" linkType="Drug"&gt;cilostazol&lt;/ulink&gt; and a Ginkgo biloba extract (presumed to be SK's Ginexin-F), which inhibits platelet activating factor, scavenges free radicals and stimulates the release of vasodilatory factors such as prostaglandin I2 and nitric oxide, for the  treatment of peripheral arterial occlusive disease and stroke [&lt;ulink linkID="1084331" linkType="Reference"&gt;1084331&lt;/ulink&gt;]. In April 2012, the agent was made available [&lt;ulink linkID="1579584" linkType="Reference"&gt;1579584&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;By December 2009, SK had submitted a filing for approval in Korea for arterial occlusive disease and  stroke  [&lt;ulink linkID="1084332" linkType="Reference"&gt;1084332&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In July 2013, a randomized, double-blind, single-center, prospective, placebo-controlled, exploratory phase III trial (&lt;ulink linkID="145387" linkType="Protocol"&gt;NCT01895400&lt;/ulink&gt;; AMC-2013-0165, 20130055275) in patients (expected n = 72) with recurrent vestibulopathy was planned to be initiated 'later that month'. The trial was expected to be completed in September 2014; in September 2013, the trial was initiated [&lt;ulink linkID="1459456" linkType="Reference"&gt;1459456&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2010, clinical data were presented at the 111th Annual Meeting of the ASCPT in Atlanta, GA. Healthy men (n = 26) received 100 mg cilostazol and 80 mg Gingko biloba extract concomitantly, or a fixed-dose combination containing the same doses. After a 7-day washout period, they were switched to the other regimen for another 7 days' dosing. Both regimens were well tolerated and showed no significant differences in pharmacokinetic parameters [&lt;ulink linkID="1079229" linkType="Reference"&gt;1079229&lt;/ulink&gt;], [&lt;ulink linkID="1084153" linkType="Reference"&gt;1084153&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2007, a phase I study (NCT00689858, GETC_DDI_I_2008) was initiated in 40 healthy volunteers in Korea, who were to receive cilostazol plus Ginkgo biloba extract or cilostazol plus placebo, or the treatments in the reverse order. The primary outcome was plasma Cmax of cilostazol. The study was completed in July 2008 [&lt;ulink linkID="1084245" linkType="Reference"&gt;1084245&lt;/ulink&gt;]. In March 2010, clinical data from this study were presented at the 111th Annual Meeting of the ASCPT in Atlanta, GA. Healthy Korean men (n =36) received oral doses of 100 mg cilostazol plus 80 mg Ginexin-F, or 100 mg cilostazol plus placebo twice daily for 7 days. After a 2-week washout period, they were switched to the other regimen for another 7 days' dosing. Ginexin-F did not affect the pharmacokinetics of cilostazol and no significant differences were detected between the two regimens in measures of blood clotting [&lt;ulink linkID="1079230" linkType="Reference"&gt;1079230&lt;/ulink&gt;], [&lt;ulink linkID="1084153" linkType="Reference"&gt;1084153&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In 2009, preclinical data were published. Cilostazol and Ginkgo biloba extract in combination inhibited platelet aggregation in vitro more than each alone. The combination also showed activity in animal models of pulmonary embolism  and arterial thrombosis. Measures of bleeding time were not increased by combination treatment [&lt;ulink linkID="1084244" linkType="Reference"&gt;1084244&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In February 2012, the Korean Intellectual Property Tribunal ruled that SK Chemicalsâ€™s patent for Renexin was valid. A patent nullification suit was filed by &lt;ulink linkID="1054436" linkType="Company"&gt;Korea Prime Pharm&lt;/ulink&gt; and &lt;ulink linkID="1006636" linkType="Company"&gt;Korea United Pharm&lt;/ulink&gt; which had been marketing generic versions of Renexin [&lt;ulink linkID="1267611" linkType="Reference"&gt;1267611&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="26914">SK Chemicals Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate>2012-04-01T00:00:00.000Z</StatusDate><Source id="1579584" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26914">SK Chemicals Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1598">Peripheral arterial occlusive disease</Indication><StatusDate>2012-04-01T00:00:00.000Z</StatusDate><Source id="1579584" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="26914">SK Chemicals Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1598">Peripheral arterial occlusive disease</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1084332" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26914">SK Chemicals Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate>2009-12-31T00:00:00.000Z</StatusDate><Source id="1084332" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26914">SK Chemicals Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1598">Peripheral arterial occlusive disease</Indication><StatusDate>2007-05-31T00:00:00.000Z</StatusDate><Source id="1084245" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01426"><Name>Nitric oxide synthase</Name><SwissprotNumbers><Swissprot>O61309</Swissprot><Swissprot>O61608</Swissprot><Swissprot>Q26240</Swissprot><Swissprot>Q27571</Swissprot><Swissprot>Q9I9M2</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01502"><Name>Platelet activating factor receptor</Name><SwissprotNumbers><Swissprot>P21556</Swissprot><Swissprot>P25105</Swissprot><Swissprot>P35366</Swissprot><Swissprot>P46002</Swissprot><Swissprot>Q62035</Swissprot><Swissprot>Q9GK76</Swissprot><Swissprot>Q9TTY5</Swissprot><Swissprot>Q9XSD4</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01521"><Name>PDE 3</Name><SwissprotNumbers><Swissprot>Q8I0P7</Swissprot></SwissprotNumbers></Target><Target id="PTGT-04986"><Name>Prostacyclin synthase</Name><SwissprotNumbers><Swissprot>O35074</Swissprot><Swissprot>Q16647</Swissprot><Swissprot>Q29626</Swissprot><Swissprot>Q62969</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>c1cc2c(cc1OCCCCc3nnnn3C4CCCCC4)CCC(=O)N2</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="1444355" number="WO-2008063025" title="Combination drug of cilostazol and ginkgo biloba extracts"/><PatentFamily id="2598372" number="WO-2013147556" title="Pharmaceutical composition for preventing or treating hearing loss, containing cilostazol and Ginkgo leaf extract as active ingredients"/><PatentFamily id="2618712" number="KR-2013113734" title="The pharmaceutical composition for the atherosclerosis prevention or treatment including the cilostazol and &lt;i&gt;Gingko&lt;/i&gt; leaf extract as an active ingredient."/><PatentFamily id="3774062" number="WO-2017146286" title="Pharmaceutical composition of ginkgo biloba leaf extract using matrix of sustained-release hydrophilic polymer, and sustained-release oral preparation using same"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="SK Group" id="26891"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>